News and Comments

Alnylam: Some Acted Without Listening and Some Listened But Did Not Believe

  Thursday, October 06, 2016

Following recent reports of new onset or worsening peripheral neuropathy in patients with ATTR amyloidosis with cardiomyopathy (hATTR-CM) treated with Alnylam’s (ALNY) RNAi –based drug revusiran, The firm requested that the Data Monitoring Committee (DMC) review the reports and the Clinical trial data on an unblinded basis. After reviewing the reports, the DMC advised suspending the dosing of revusiran.   More...

Why Aerie Pharmaceuticals' Stock Rallied Today. What About Now?

  Thursday, September 15, 2016


Another CRISPR Gene Editing Company Decided to Go Public. What's Investors' Decision?

  Tuesday, September 13, 2016

Another gene editing firm, CRISPR Therapeutics decided to become publicly traded. On Friday, the private firm filed with the SEC planning for a $90 million initial public offering (IPO).    More...

Nektar Therapeutics: Crossing the Barriers and Sailing into the Future

  Tuesday, September 06, 2016

Filled with high hopes and great enthusiasm, we are following up on Nektar’s (NKTR) immunotherapy product NKTR-214, which is in trials by Mayo Clinic and MD Anderson cancer center. The product is a CD122-biased agonist designed to stimulate the patient's own immune system to kill tumor cells. The technology behind the molecule “targeted polymer conjugate technology” has been validated time and time again in clinical trials and in approved drugs marketed by Nektar partners mainly large pharmaceutical firms.  NKTR-214 uses Nektar's this technology to enable preferential activation of immunostimulatory IL-2 receptors. It is a novel mechanism of action in immunotherapy, which is what is attracting us to the drug, knowing in fact that existing IL-2 therapy activates both immunosuppressive as well as immune-stimulatory receptors, which has limited its utility in clinical settings before the surfacing of NKTR-214. More...

A New Option for Osteoporosis Treatment That Would Prevent Bone Fractures

  Tuesday, August 23, 2016

JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women with Osteoporosis More...

Is Advaxis Finally Running on the Right Track?

  Wednesday, August 17, 2016

Advaxis (ADXS) is a small clinical-stage biotech producing and developing cancer immunotherapy products based on its proprietary Lm Technology. The technology uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria. It is said that Adraxis therapeutics cancer immunotherapy agents are the first to generate cancer fighting T cells against cancer antigens in early testing. They could also neutralize myeloid-derived suppressor cells (MDSCs), which protect the tumor microenvironment from immunologic attack and contribute to tumor growth.  More...

Biotech Firms With Approaches Born To Stay and Succeed

  Wednesday, August 10, 2016

Immunotherapy More...

Why BMY News Is Not Bad As Hysterical Investors Believed

  Friday, August 05, 2016


Adaptimmune EMA Privileges. Different Fate for Plummeting Stocks

  Monday, August 01, 2016

The EMA has created Priority Medicines (PRIME) regulatory initiative for products, which the European agency rules they are of unmet needs. PRIME makes them eligible for support, possible regulatory applications and potential accelerated reviews. PRIME has accepted Adaptimmune’s (ADAP) drug NY-ESO-targeting T-cell therapy. The drug became the 8th accepted for EMA’s PRIME program.   More...

Moderna Is a Private Revolutionary Biotech Firm That Investors Should Not Ignore

  Tuesday, July 26, 2016

We love to present to you Moderna, a firm that, we believe, is building revolutionary pipeline products. We mean it when we say revolutionary. The time has come for Moderna to be heard of by serious investors. It is still private, but it is revolutionary and is working with the publicly-traded firms AstraZeneca (AZN), Merck (MRK), and Vertex (VRTX) to bring what we believe will be game changing approaches for the management of intractable, untreatable and deadly diseases.   More...

Recent Postings



ABBVIE (ABBV) Dynavax (DVAX) Bristol-Myers Squibb (BMY) Intermune (ITMN) NANTKWEST (NK) Telaprevir Anadys (ANDS) Alder Biopharmaceuticals (ALDR) Agenus (AGEN PORTOLA (PTLA) Prosensa (RNA) Sanofi-Aventis (SAN) MODERNA ARGOS (ARGS) VANDA (VNDA) Mirati Therapeutics (MRTX) Benlysta (belimumab) Endometrial Cancer PTC Therapeutics (PTCT) SERES THERAPEUTICS (MCRB) CEMPRA (CEMP) Vertex (VRTX) RenenxBio (RGNX) NOVOCURE (NVCR) CompuGen (CGEN) Sarepta (SRPT) Dendreon (DNDN) ARCA (ABIO) Sanofi (SNY) Multiple Myeloma Cytokinetics (CYTK) Rapamune Ocular Therapeutix (OCUL) Herceptin Biocryst (BCRX) Revlimid (lenolidamide) Zerenex Idenix (IDIX) Regeneron (REGN) Velcade (bortezomib) Galena (GALE) Advaxis (ADXS) IDERA (IDRA) AGOS (ARGS) BIOMARIN (BMRN) Ridaforolimus Human Longevity (HLI) ImmunoGen (IMGN) ADVENTRIX (ANX) CRISPR Therapeutics (CRSP) Array Pharmaceuticals (ARRY) Onyx (ONXX) Inovio (INO) ISIS (ISIS) Jazz Pharmaceuticals (JAZZ) AERIE PHARMACEUTICALS Genentech GlaxoSmithKline (GSK) AstraZeneca (AZN) Biogen Idec (BIIB) Prolor Biotech (PBTH) SUNESIS PHARMACEUTICALS (SNSS) Ziofpharm (ZIOP) Abbott Laboratories (ABT) KERYX (KERX) Tysabri Roche (RHHBY) Valeant Pharmaceuticals International (VRX) Xoma (XOMA) Micromet (MITI) REGULUS (RGLS) TOKAI (TKAOI) Agenus (AGEN) Elan (ELN) Ariad (ARIA) Gilead (GILD) Sanofi (SNA) Anacor (ANAC) Editas (EDIT) Human Genome Sciences (HGSI) ACADIA (ACAD) Amgen (AMGN) Illumina (ILMN) Trastuzumab-DM1 Exelixis (EXEL) Incyte (INCY) Alnylam (ALNY) Intercept (ICPT) Intrexon (XON) Seattle Genetics (SGEN) OSI (OSIP) ZALTRAP™ Sequenom (SQNM) Global Cell Therapeutics (GBT) HALOZYME (HALO) NEKTAR (NKTR)) galapagos (GLPG) Roche (ROCHE) KITE (KITE) Sangamo (SGMO) SYNTA (SNTA) Spike Therapeutics (ONCE) Merck (MRK) Bellicum (BLCM) Theravance (THRX) Adaptimmune (ADAP) GUARDIAN HEALTH INNOVIVA (INVA) Vitae Pharmaceuticals (VTAE) Pluristem (PSTI) Aimmune Therapeutics (AIMT) Auspex (ASPX) C4 Therapeutics JUNO (JUNO) Ionis (IONS) Theravance Bio Pharma (TBPH)